|
Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S) |
|
|
|
Title: |
Phase 3 Randomized Study (ARCHER 1050) of 1st-Line Dacomitinib vs Gefitinib for Advanced NSCLC with EGFR Mutation(S) |
Author: |
Mok, T.S.K. Nakagawa, K. Rosell, R. Wu, Y.-l. Trygstad, C. Capizzi, R. DeBenedetto, R. Goldberg, Z. Wang, T. Antic, V. |
Appeared in: |
Annals of oncology |
Paging: |
Volume 24 () nr. S9 pages ix44 |
Year: |
2013 |
Contents: |
|
Publisher: |
European Society for Medical Oncology |
Source file: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|